Latest News - Imprimis Pharmaceuticals

Thursday, May 04, 2017 | Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Launches Simple Drops Combination Glaucoma Drops

Imprimis Pharmaceuticals announced the launch of its new patent-pending Simple Drops preservative-free glaucoma drops at the American Society of Cataract and Refractive Surgery (ASCRS) 2017 meeting in…

Read the full story

Tuesday, May 02, 2017 | Partnerships, Imprimis Pharmaceuticals, SightLife Surgical

Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears

Imprimis Pharmaceuticals announced the signing of an exclusive strategic sales and marketing agreement. Under the agreement, SightLife Surgical will deploy their sales team to offer Imprimis’ Se…

Read the full story

Tuesday, April 18, 2017 | Partnerships, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis’ Ophthalmic Portfolio Market

Imprimis Pharmaceuticals and Cameron Ehlen Group, d/b/a Precision Lens, announced the signing of a 3-year exclusive sales representation agreement. Under the agreement, Precision Lens will deploy a de…

Read the full story

Thursday, April 06, 2017 | Acquisitions/Mergers, Dry Eye, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease

Imprimis Pharmaceuticals announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients…

Read the full story

Monday, March 20, 2017 | Cataract Surgery, Medical Studies, Imprimis Pharmaceuticals

Peer-Reviewed Paper Demonstrates the Benefits of Dropless Cataract Surgery

Imprimis Pharmaceuticals, an ophthalmology-focused pharmaceutical company, today announced the publication of a dropless therapy article in the peer-reviewed journal, Current Pharmaceutical Desig…

Read the full story

Thursday, February 16, 2017 | Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility

Imprimis Pharmaceuticals announced that it has begun shipping its core sterile ophthalmic medications to select customers from its FDA-registered outsourcing facility without the need for a patient-sp…

Read the full story

Thursday, November 17, 2016 | Awards, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Ranked 12 on Deloitte’s 2016 Technology Fast 500 List of Fastest Growing Companies in North America

Imprimis Pharmaceuticals announced that it ranked 12 on Deloitte’s Technology Fast 500, an annual ranking of the fastest growing North American companies in the technology, media, telecommunicat…

Read the full story

Friday, October 28, 2016 | Miscellaneous, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Registers its New Jersey Facility with the FDA as an Outsourcing Facility

Imprimis Pharmaceuticals announced that it has filed for registration of its recently-constructed New Jersey facility with the FDA as a 503B outsourcing facility. The facility is expected to begin man…

Read the full story

Tuesday, October 25, 2016 | Clinical Trials, Imprimis Pharmaceuticals

Imprimis' Dropless Therapy Shows Significant Advantages in a Large Peer-Reviewed Study

Imprimis Pharmaceuticals announced the release of data from a peer-reviewed study of patients receiving Imprimis' proprietary Dropless Therapy following cataract surgery, according to a company ne…

Read the full story

Thursday, October 13, 2016 | Conferences, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals’ Formulations to be Highlighted at Upcoming Annual Ophthalmology Meeting in Chicago

Imprimis Pharmaceuticals announced events featuring its ophthalmic formulations at the annual American Academy of Ophthalmology meeting in Chicago. Imprimis will host an Open House on Friday, Oct…

Read the full story

Thursday, September 22, 2016 | Health Care, Imprimis Pharmaceuticals

Following Congressional Hearing Investigating Mylan and Epi-Pen, Imprimis Pharmaceuticals Founder and CEO Publishes Drug Pricing Monograph

Imprimis Pharmaceuticals published a 75-page drug pricing monograph describing specific proposals that will drive competition, transparency, and patient access by lowering drug costs for Americans, ac…

Read the full story

Tuesday, September 06, 2016 | Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares Compounded Formulations

Imprimis Pharmaceuticals announced the launch of the Imprimis Cares Access Network (ICAN), a new patient assistance program designed to simplify the process of accessing Imprimis' patent-pend…

Read the full story

Tuesday, August 30, 2016 | Health Care, Imprimis Pharmaceuticals

Challengers Eye a Piece of EpiPen Market as Pricing Scandal Engulfs Mylan

Amid a tidal wave of backlash from politicians, media, consumers and others over its prices for EpiPen, Mylan Monday said it would roll out a generic copy of the star product. But other products are a…

Read the full story

Monday, August 15, 2016 | Management/Leadership, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Expands its Leadership Team in Operations, Quality, Manufacturing, and Client Relations

Imprimis Pharmaceuticals reported the expansion of its leadership team with the appointments of Clayton Edwards as Senior Vice President of Operations; Eric Rice as Vice President of Client Relations;…

Read the full story

Friday, July 29, 2016 | Product Releases, Imprimis Pharmaceuticals

Imprimis Launches New MaxRx Prescriber Portal

Imprimis Pharmaceuticals announced the availability of its new MaxRx Prescriber Portal, a software application that provides physicians with new order entry and management tools that have traditionall…

Read the full story
Load More